SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

Temab-A

ABBV·AbbVie Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
Likely several years away; Phase 3 trials are recruiting with primary completion estimated around 2029 for the colorectal cancer trial. Breakthrough Therapy Designation could enable accelerated FDA review if AbbVie files based on interim data, but no filing has been announced.
Why 4/10
No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled in the next ~12 months; the Phase 3 AndroMETa trials are still recruiting with primary completion estimated around 2029, and no regulatory filing has been announced. Temab-A is also one of many pipeline programs at a mega-cap diversified pharma, limiting its share-price impact.
Actionable Insight NEUTRAL

The next major catalysts for Temab-A will be interim or final Phase 3 data readouts from the AndroMETa-CRC-560 (NCT07525206) and AndroMETa-Lung-713 (NCT07155187) trials, but these are likely years away (primary completion estimated around 2029 for CRC). Watch for potential accelerated filing based on the Breakthrough Therapy Designations, which could compress the timeline, but no regulatory submission has been announced yet.

Price Chart

Loading chart...

Executive Summary

Temab-A (telisotuzumab adizutecan, ABBV-400) is AbbVie's next-generation antibody-drug conjugate targeting the c-Met protein, which is overexpressed in many solid tumors. On October 7, 2026, the FDA granted it two Breakthrough Therapy Designations for colorectal cancer (in combination with bevacizumab) and non-small cell lung cancer (as monotherapy), based on encouraging Phase 1 data. The drug is now in multiple Phase 3 trials (AndroMETa program) that are actively recruiting, with primary completion estimated around 2029. For AbbVie, a mega-cap diversified pharma with roughly $61 billion in annual revenue and a market cap near $295 billion, Temab-A is a promising but early-stage pipeline asset. No PDUFA date or pivotal readout is imminent, limiting its near-term stock-moving potential.

How It Works

Temab-A is an antibody-drug conjugate (ADC), a type of precision cancer therapy. It works like a guided missile: one part of the drug (the antibody) latches onto a protein called c-Met that is found in high amounts on the surface of many cancer cells, and the other part delivers a chemotherapy payload (a topoisomerase 1 inhibitor) directly inside those cells, killing them while largely sparing healthy tissue.

Trial Status

Temab-A is in multiple Phase 3 and Phase 2/3 trials across colorectal cancer (AndroMETa-CRC-560, NCT07525206, recruiting ~990 patients) and non-small cell lung cancer (AndroMETa-Lung-713, NCT07155187). Additional Phase 2 studies are exploring gastric, esophageal, and head and neck cancers. The Phase 1 first-in-human study (NCT05029882) has reported encouraging efficacy data in heavily pretreated patients, which supported the Breakthrough Therapy Designations.

The Two-Sided Case

▲ Bull Case4
Temab-A received two FDA Breakthrough Therapy Designations in October 2026 for both colorectal cancer and non-small cell lung cancer, a strong regulatory endorsement that can accelerate development and review timelines.
Early Phase 1 data (NCT05029882) showed clinically meaningful efficacy in heavily pretreated patients, with the 2.4 mg/kg + bevacizumab dose selected for Phase 3 based on favorable risk-benefit.
AbbVie is positioning Temab-A as a 'pipeline-in-a-molecule' across at least seven tumor types, including gastric, esophageal, and head and neck cancers, expanding its addressable market.
As a next-generation ADC with a Top1i payload, Temab-A is designed to overcome resistance to earlier c-Met ADCs like Emrelis (telisotuzumab vedotin), offering a potential upgrade cycle.
▼ Bear Case4
Temab-A is still in Phase 3 trials that are actively recruiting; no pivotal data has been published yet, and the BTDs were based on early-phase data that has not been fully peer-reviewed.
The c-Met ADC space is competitive, with other developers pursuing similar targets; Temab-A must differentiate on efficacy and safety to capture market share.
For a mega-cap like AbbVie (~$295B market cap, ~$61B revenue), Temab-A is one of many pipeline assets and is unlikely to be a near-term stock-moving catalyst.
Phase 3 trials carry inherent risk of failure or underwhelming results, and the primary completion dates extend to 2029-2030, meaning commercial revenue is years away.

Upcoming Catalysts

  • Potential interim data from ongoing Phase 3 AndroMETa trials (timing uncertain, likely 2027+ given 2029 primary completion estimates)
  • Possible accelerated regulatory filing based on Breakthrough Therapy Designation (no announcement yet)
  • Additional data presentations at major medical conferences (ASCO, ESMO, WCLC, ESMO)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbbVie Inc. 8-K ABBV ·Originating report

Sources · 9

Hover a chip for the title
1 news.abbvie.com2 ascopubs.org3 pharmexec.com4 ascopubs.org5 dashboard.datalookout.com6 clintrialfinder.info7 news.abbvie.com8 targetedonc.com9 pubmed.ncbi.nlm.nih.gov